spacer
home > ebr > summer 2018 > natural intelligence looks at ai
PUBLICATIONS
European Biopharmaceutical Review

Natural Intelligence Looks at AI

Artificial intelligence (AI) is the fourth industrial revolution. Machinelearning, Big Data, and basic science have reached a tipping point where the question is not if, but when. Media coverage of AI is abuzz with driverless cars, facial recognition, and data analytics. However, public reception is divided. Is it a positive transformation of the human condition or a brave new world? Nations and industries alike have embraced AI, fearing to be left behind in the race for global competitive advantage.

AI is now being adopted by all the major biopharmaceutical companies at every stage of their pipeline workflows. Industrial and academic research centres and a spate of new startups and investors are all sprinting towards this new reality. Still, the hype and skepticism surrounding biotechnology applications of AI echoes earlier paradigm shifts in the drug discovery – high throughput screening, molecular modelling, and rational design. Critics say these never lived up to the promise, yet they continue to play an important role in drug discovery today.

What Is AI?

AI consists of software systems based on the confluence of computing power, large data sets, and models that mimic the understanding of the human brain. They attempt to self-learn from training sets of data and develop the ability to interpret new inputs. They provide reasoned outputs and predictions in new situations. These learning engines are model-free. Cause-and-effect is not as obvious as one might expect in a linear regression or a decision tree. Simultaneously, they achieve a high level of predictive accuracy in datasets that are too large and multidimensional for an individual to handle.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, a Chinawatcher, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>

White Papers

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

RSSL

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement